Cellectar Biosciences
CLRB
7 hedge funds and large institutions have $5.13M invested in Cellectar Biosciences in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
17% more funds holding
Funds holding: 6 → 7 (+1)
8.18% less ownership
Funds ownership: 51.4% → 43.21% (-8.2%)
86% less capital inflows, than outflows
Capital inflows: $91K | Capital outflows: $637K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$546K |
| 2 |
AIC
AWM Investment Company
New York
|
-$91K |
CLRB Hedge Fund Activity: Q3 2015 in Review
7 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2015, worth a combined $5.13M — down 32% from $7.52M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CLRB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $91K. The largest seller was Sabby Management, cutting an estimated $546K.
- 7 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2015, up from 6 in Q2 2015.
- Funds reported $5.13M of Cellectar Biosciences stock for Q3 2015, down 32% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences positions in Q3 2015 and 0 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences buyer in Q3 2015 was Geode Capital Management, an estimated $91K added.
- The largest Cellectar Biosciences seller in Q3 2015 was Sabby Management, an estimated $546K sold.
Based on aggregated 13F filings for Q3 2015.